SCHEMBL26129010

SCHEMBL26129010

CCc1cccc(CC)c1-c1cc(Cl)nc(N(C(=O)OC(C)(C)C)C(=O)OC(C)(C)C)n1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 2/20 0.38
HSP90AB1 P08238 2/20 0.38
NQO2 P16083 1/20 0.36
ACACB O00763 1/20 0.34
ACACA Q13085 1/20 0.34
C5AR1 P21730 6/20 0.33
SYK P43405 1/20 0.33
ADCY10 Q96PN6 1/20 0.32
STK17B O94768 1/20 0.32
STK17A Q9UEE5 1/20 0.32
KDM4A O75164 1/20 0.32
MEN1 O00255 1/20 0.31
LMNA P02545 1/20 0.31
TSHR P16473 1/20 0.31
KMT2A Q03164 1/20 0.31
CKS1B P61024 1/20 0.31
SKP1 P63208 1/20 0.31
SKP2 Q13309 1/20 0.31
PAX8 Q06710 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30588742 1.00 HSP90AA1 (0.38) HSP90AA1HSP90AB1NQO2ACACBACACA
SCHEMBL26125824 0.94 HSP90AA1 (0.36) HSP90AA1HSP90AB1NQO2ACACBACACA
SCHEMBL31075134 0.88 PPARA (0.36) HSP90AA1HSP90AB1NQO2LMNATSHR
SCHEMBL22502015 0.87 HSP90AA1 (0.41) HSP90AA1HSP90AB1NQO2ACACBACACA
SCHEMBL22502018 0.84 HSP90AA1 (0.36) HSP90AA1HSP90AB1NQO2ACACBACACA
SCHEMBL22501987 0.81 HSP90AA1 (0.39) HSP90AA1HSP90AB1NQO2ACACBACACA
SCHEMBL31546947 0.81 HSP90AA1 (0.39) HSP90AA1HSP90AB1NQO2ACACBACACA
SCHEMBL18167877 0.80 STK17B (0.37) HSP90AA1HSP90AB1NQO2ACACBACACA
SCHEMBL24323283 0.80 LMNA (0.37) HSP90AA1HSP90AB1LMNA
SCHEMBL29600537 0.80 LMNA (0.37) HSP90AA1HSP90AB1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250340574-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMA (US) 2025-11-06 US disclosed
EP-4504739-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR Vertex Pharmaceuticals Incorporated (US) 2025-02-12 EP disclosed
WO-2023196429-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-12 WO disclosed
WO-2023196429-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250340574-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B HSP90AA1 1225/4885HSP90AB1 793/4885NQO2 1265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.